XXEC Inc. Buys 236,761 Shares of Heartflow, Inc. $HTFL

XXEC Inc. lifted its stake in shares of Heartflow, Inc. (NASDAQ:HTFL) by 564.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 278,681 shares of the company’s stock after purchasing an additional 236,761 shares during the period. Heartflow accounts for 1.3% of XXEC Inc.’s investment portfolio, making the stock its 18th biggest holding. XXEC Inc.’s holdings in Heartflow were worth $6,780,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Heartflow by 20.8% during the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares during the period. Bamco Inc. NY lifted its position in shares of Heartflow by 86.2% during the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after buying an additional 1,066,371 shares during the last quarter. Schusterman Interests LLC bought a new position in shares of Heartflow during the 3rd quarter worth $65,274,000. Capricorn Investment Group LLC bought a new position in shares of Heartflow during the 4th quarter worth $48,178,000. Finally, Vanguard Group Inc. increased its holdings in Heartflow by 8.8% in the 4th quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock worth $46,066,000 after acquiring an additional 128,400 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. William Blair initiated coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. JPMorgan Chase & Co. reduced their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Finally, Canaccord Genuity Group lowered their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Heartflow Trading Down 15.8%

Heartflow stock opened at $29.34 on Wednesday. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The firm has a market capitalization of $2.53 billion and a PE ratio of -9.43. The firm’s 50 day simple moving average is $30.75 and its 200 day simple moving average is $28.67.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The firm’s quarterly revenue was up 41.3% compared to the same quarter last year. Research analysts forecast that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Insider Activity at Heartflow

In related news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11. Following the sale, the insider directly owned 8,448,158 shares of the company’s stock, valued at $246,939,658.34. This trade represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John C.M. Farquhar sold 38,900 shares of Heartflow stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the sale, the chief executive officer directly owned 457,935 shares of the company’s stock, valued at $16,027,725. This represents a 7.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,115,805 shares of company stock valued at $62,422,505. Company insiders own 7.70% of the company’s stock.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.